Click to download the PDF to view the full issue With the Zyprexa era over, Lilly is betting big on its ability to innovate in the pipeline. This past year […]
Click to download the PDF to view the full issue J&J emerged from a transitional 2012 continuing to generate annual sales increases and make significant advances on multiple fronts; the […]
Click to download the PDF to view the full issue The worst is not yet over for the pharma industry. Despite a general sense from many companies that the worst […]
Click to download the PDF to view the full issue Although the company’s long-time best seller Plavix fell off patent in 2012, a number of Bristol-Myers Squibb’s newer compounds – […]
Click to download the PDF to view the full issue With revenue of more than $20 billion, the largest generics portfolio globally, the world’s leading multiple sclerosis product, and a […]
Click to download the PDF to view the full issue Battered by the expiration of exclusivity of blockbuster products, Sanofi is driven to grow other areas of its business. The […]